Sir, Sexual transmission of HIV-1 is currently the major way of viral spread worldwide: the quantification of seminal HIV-1 RNA has been clearly linked to the risk of transmission. 1 The use of highly active antiretroviral treatment, besides providing immunovirological benefits, has been associated with viral control in the genital compartment of males and females. Nevertheless, occasional HIV-1 shedding has been demonstrated despite effective systemic therapy: insufficient penetration of antiretrovirals has been advocated as one of the reasons for HIV-1 compartmentalization. 2 Although dual therapy and monotherapy have been shown to be effective in the majority of stable HIV-infected patients, limited data exist on their effectiveness in the genital compartment. 3 Furthermore, the optimal maraviroc dosage when administered with boosted protease inhibitors is still debated: 150 mg once daily showed promising antiviral efficacy when combined with lopinavir/ritonavir and lower than expected results in association with atazanavir/ritonavir and darunavir/ ritonavir. 4, 5 The primary aim of this study was to describe the seminal pharmacokinetics of maraviroc (150 mg once daily) when given in association with lopinavir/ritonavir. The secondary objective was to analyse seminal HIV-1 replication in patients receiving this dual regimen.
Adult male patients enrolled in the VEMAN protocol 4 were eligible for this substudy. The main inclusion criteria were no concomitant systemic or genital illness, a confirmed viral load ,37 copies/mL, to be on protocol between weeks 48 and 96 and no coadministration of potentially interacting drugs. A written informed consent was signed by each participant after approval by the San Raffaele Scientific Institute Ethics Committee, Milan, Italy. Blood plasma and seminal plasma levels were measured by a validated ultraperformance liquid chromatography coupled with triple-quadrupole mass spectrometry method with a limit of detection of 0.125 ng/mL. Plasma HIV RNA was measured through a kinetic PCR molecular system (kPCR) (Versant HIV-1 RNA kPCR 1.0; Siemens Diagnostics) with a limit of quantification of 37 copies/mL. Seminal plasma HIV RNA was measured through an NASBA TM -based real-time amplification using NucliSENS EasyQ w HIV-1 v2.0 (with a detection rate of 79% at 500 copies/mL). 6 Mann -Whitney and x 2 tests were used to test differences between variables while Spearman's r was used to quantify the significance of correlations. Data are expressed as medians (IQRs); coefficient of variation (CV) was calculated as standard deviation/average.
Ten male patients were enrolled [aged 39.6 years (34.3-45.8) and with a body mass index of 23.5 kg/m 2 (22.2 -29.4)]. All patients had HIV RNA ,37 copies/mL and the CD4 cell count was 619 cells/mm 3 (547 -683). Plasma and seminal samples were collected 11.6 (10.1 -12.4) and 9.2 (8 -11.5) h after maraviroc intake, respectively. Maraviroc plasma and seminal concentrations were 223 ng/mL (103.9 -312, CV 55.4%) and 527 ng/mL (234 -852, CV 89.8%), respectively. The maraviroc seminal plasma-to-plasma ratio (ratio SP-P ) was 291.6% (103.9%-405.1%, CV 80.5%) (Figure 1 ). Lopinavir plasma and seminal concentrations were 7935 ng/mL (6269 -8958) and 233 ng/mL (136 -803), respectively. The lopinavir ratio SP-P was 4.3% (2.6% -11.7%). Ritonavir plasma and seminal concentrations were 275 ng/mL (224 -773) and 21 ng/mL (7 -31), respectively. The ritonavir ratio SP-P was 8.3% (4.6%-10.7%).
The included patients were compared with five male patients in the control arm (receiving tenofovir/emtricitabine plus lopinavir/ ritonavir), who were aged 43 years (37.3 -44), had a body mass index of 22.3 kg/m 2 (21.5 -24.8) and had a CD4 cell count of 480 cells/mm 3 (449-531). Lopinavir plasma and seminal concentrations and ratio SP-P were 11521 ng/mL (10111-14018), 517 ng/mL (461-634) and 6.3% (3.3%-6.6%), respectively. Ritonavir plasma and seminal concentrations and ratio SP-P were 436 ng/mL (424-900), 18 ng/mL (16 -35) and 6.2% (1.3% -8.1%), respectively. While RNA amplification was not effective in two samples, seminal HIV RNA was undetectable in all others (n¼13). This is the first report of maraviroc pharmacokinetics in seminal plasma when dosed at 150 mg once daily with a boosted protease inhibitor. Maraviroc accumulated in seminal plasma and compartmental maraviroc concentrations were found to be adequate and well above the protein-free 90% inhibitory concentration (IC 90 ) (0.5 ng/mL) in all included subjects.
Lopinavir and ritonavir exposures in seminal plasma were similar to previous reports. In previous studies, maraviroc administered twice daily (150, 300 or 600 mg) 7 -10 showed median seminal concentrations between 80 and 804 ng/mL, being 89%-970% of plasma levels with a large interpatient variability (seminal levels ranging from 15.8 to 4920 ng/mL). Interestingly, in our patients both plasma and seminal maraviroc exposure were comparable to the values previously reported for maraviroc # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com at double dosing (150 mg twice daily) with darunavir/ritonavir. This finding further supports the pharmacological suitability of once-daily dosing of 150 mg of maraviroc with lopinavir/ritonavir. Moreover, pharmacological findings were consistent with virological data: both in patients in the experimental dual-regimen arm and in the triple-drug arm, seminal plasma HIV RNA was undetectable. These data support the seminal virological effectiveness of the once-daily maraviroc plus lopinavir/ritonavir association and confirm, in general terms, the results of previous data on protease inhibitor-based dual regimens in the male genital tract. 3 In conclusion, once-daily maraviroc at 150 mg administered with lopinavir/ritonavir showed adequate seminal exposure and full antiviral activity in the male genital tract.
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